Page 113 - 《中国药房》2026年4期

Lancet，2011，377（9763）：393-402. [19] 孙琼，王红祥，陈莉，等. 重组人血小板生成素和海曲泊
[11] TOMIYAMA Y，MIYAKAWA Y，OKAMOTO S，et al. A 帕对原发免疫性血小板减少症患者免疫功能影响的分
lower starting dose of eltrombopag is efficacious in Japanese 析[J]. 国际输血及血液学杂志，2024，47（6）：503-511.
patients with previously treated chronic immune thrombo‐ [20] GONZALEZ-PORRAS J R，BASTIDA J M. Eltrombopag
cytopenia[J]. J Thromb Haemost，2012，10（5）：799-806. in immune thrombocytopenia：efficacy review and update
[12] BUSSEL J B，KUTER D J，ALEDORT L M，et al. A ran‐ on drug safety[J]. Ther Adv Drug Saf，2018，9（6）：
domized trial of avatrombopag， an investigational 263-285.
thrombopoietin-receptor agonist，in persistent and chronic [21] DENG Y L，MADATIAN A，WIRE M B，et al. Metabo‐
immune thrombocytopenia[J]. Blood，2014，123（25）： lism and disposition of eltrombopag，an oral，nonpeptide
3887-3894. thrombopoietin receptor agonist，in healthy human sub‐
[13] YANG R C，LI J M，JIN J，et al. Multicentre，randomised jects[J]. Drug Metab Dispos，2011，39（9）：1734-1746.
phase Ⅲ study of the efficacy and safety of eltrombopag [22] MARKHAM A. Avatrombopag：a review in thrombocyto‐
in Chinese patients with chronic immune thrombocytope‐ penia[J]. Drugs，2021，81（16）：1905-1913.
nia[J]. Br J Haematol，2017，176（1）：101-110. [23] SALEH M N，BUSSEL J B，CHENG G，et al. Safety and
[14] 黄月婷，刘晓帆，陈云飞，等. 艾曲泊帕治疗成人慢性原 efficacy of eltrombopag for treatment of chronic immune
发免疫性血小板减少症的疗效及安全性[J]. 中华血液学 thrombocytopenia：results of the long-term，open-label
杂志，2018，39（1）：32-36. EXTEND study[J]. Blood，2013，121（3）：537-545.
[15] JURCZAK W，CHOJNOWSKI K，MAYER J，et al. Phase [24] ZHANG P，MIAO W J. Eltrombopag-induced liver dys‐
3 randomised study of avatrombopag，a novel thrombo- function during the treatment of immune thrombocyto-
poietin receptor agonist for the treatment of chronic immune penia and its risk factors[J]. Ann Palliat Med，2021，10
thrombocytopenia[J]. Br J Haematol，2018，183（3）： （6）：6419-6424.
479-490. [25] WANG X L，LI Y S，ZHUANG W. Safety analysis of
[16] ARNOLD D M，HEDDLE N M，COOK R J，et al. Perio- romiplostim，eltrombopag，and avatrombopag post-market
perative oral eltrombopag versus intravenous immuno‐ approval：a pharmacovigilance study based on the FDA
globulin in patients with immune thrombocytopenia：a Adverse Event Reporting System[J]. BMC Pharmacol
non-inferiority，multicentre，randomised trial[J]. Lancet Toxicol，2025，26（1）：46.
Haematol，2020，7（9）：e640-e648. [26] TERRAULT N，CHEN Y C，IZUMI N，et al. Avatrom‐
[17] MEI H，LIU X F，LI Y，et al. A multicenter，randomized bopag before procedures reduces need for platelet transfu‐
phase Ⅲ trial of hetrombopag：a novel thrombopoietin sion in patients with chronic liver disease and thrombocy‐
receptor agonist for the treatment of immune thrombocyto‐ topenia[J]. GASTroenterology，2018，155（3）：705-718.
penia[J]. J Hematol Oncol，2021，14（1）：37. [27] WONG R S M，SALEH M N，KHELIF A，et al. Safety
[18] MEI H，XU M，YUAN G L，et al. A multicentre double- and efficacy of long-term treatment of chronic/persistent
blind，double-dummy，randomised study of recombinant ITP with eltrombopag：final results of the EXTEND study
human thrombopoietin versus eltrombopag in the treat‐ [J]. Blood，2017，130（23）：2527-2536.
ment of immune thrombocytopenia in Chinese adult pa‐ （收稿日期：2025-09-24 修回日期：2026-01-23）
tients[J]. Br J Haematol，2021，195（5）：781-789. （编辑：陈 宏）

中国药房 2026年第37卷第4期 China Pharmacy 2026 Vol. 37 No. 4 · 515 ·